Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila - PubMed (original) (raw)
. 2000 Nov 22;9(19):2811-20.
doi: 10.1093/hmg/9.19.2811.
Affiliations
- PMID: 11092757
- DOI: 10.1093/hmg/9.19.2811
Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila
H Y Chan et al. Hum Mol Genet. 2000.
Abstract
At least eight dominant human neurodegenerative diseases are due to the expansion of a polyglutamine within the disease proteins. This confers toxicity on the proteins and is associated with nuclear inclusion formation. Recent findings indicate that molecular chaperones can modulate polyglutamine pathogenesis, but the basis of polyglutamine toxicity and the mechanism by which chaperones suppress neurodegeneration remains unknown. In a Drosophila: disease model, we demonstrate that chaperones show substrate specificity for polyglutamine protein, as well as synergy in suppression of neurotoxicity. Our analysis also reveals that chaperones alter the solubility properties of the protein, indicating that chaperone modulation of neurodegeneration in vivo is associated with altered biochemical properties of the mutant polyglutamine protein. These findings have implications for these and other human neurodegenerative diseases associated with abnormal protein aggregation.
Similar articles
- Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases.
Ghosh S, Feany MB. Ghosh S, et al. Hum Mol Genet. 2004 Sep 15;13(18):2011-8. doi: 10.1093/hmg/ddh214. Epub 2004 Jul 14. Hum Mol Genet. 2004. PMID: 15254017 - Chaperone suppression of cellular toxicity of huntingtin is independent of polyglutamine aggregation.
Zhou H, Li SH, Li XJ. Zhou H, et al. J Biol Chem. 2001 Dec 21;276(51):48417-24. doi: 10.1074/jbc.M104140200. Epub 2001 Oct 17. J Biol Chem. 2001. PMID: 11606565 - Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70.
Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, Bonini NM. Warrick JM, et al. Nat Genet. 1999 Dec;23(4):425-8. doi: 10.1038/70532. Nat Genet. 1999. PMID: 10581028 - [Neurodegenerative polyglutamine expansion diseases: physiopathology and therapeutic strategies].
Ravache M, Abou-Sleymane G, Trottier Y. Ravache M, et al. Pathol Biol (Paris). 2010 Oct;58(5):357-66. doi: 10.1016/j.patbio.2009.12.004. Epub 2010 Mar 29. Pathol Biol (Paris). 2010. PMID: 20299163 Review. French. - Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.
Reis SD, Pinho BR, Oliveira JMA. Reis SD, et al. Mol Neurobiol. 2017 Oct;54(8):5829-5854. doi: 10.1007/s12035-016-0120-z. Epub 2016 Sep 22. Mol Neurobiol. 2017. PMID: 27660272 Review.
Cited by
- Two novel DnaJ chaperone proteins CG5001 and P58IPK regulate the pathogenicity of Huntington's disease related aggregates.
Deo A, Ghosh R, Ahire S, Marathe S, Majumdar A, Bose T. Deo A, et al. Sci Rep. 2024 Sep 6;14(1):20867. doi: 10.1038/s41598-024-71065-3. Sci Rep. 2024. PMID: 39242711 Free PMC article. - The Role of Protein Quantity Control in Polyglutamine Spinocerebellar Ataxias.
Zhang H, Wang X. Zhang H, et al. Cerebellum. 2024 Jul 25. doi: 10.1007/s12311-024-01722-w. Online ahead of print. Cerebellum. 2024. PMID: 39052145 Review. - Chronic exposure to the star polycation (SPc) nanocarrier in the larval stage adversely impairs life history traits in Drosophila melanogaster.
Yan S, Li N, Guo Y, Chen Y, Ji C, Yin M, Shen J, Zhang J. Yan S, et al. J Nanobiotechnology. 2022 Dec 8;20(1):515. doi: 10.1186/s12951-022-01705-1. J Nanobiotechnology. 2022. PMID: 36482441 Free PMC article. - Hsc70-4 aggravates PolyQ-mediated neurodegeneration by modulating NF-κB mediated immune response in Drosophila.
Rai S, Tapadia MG. Rai S, et al. Front Mol Neurosci. 2022 Nov 8;15:857257. doi: 10.3389/fnmol.2022.857257. eCollection 2022. Front Mol Neurosci. 2022. PMID: 36425218 Free PMC article. - HSF1 and Its Role in Huntington's Disease Pathology.
Kim H, Gomez-Pastor R. Kim H, et al. Adv Exp Med Biol. 2023;1410:35-95. doi: 10.1007/5584_2022_742. Adv Exp Med Biol. 2023. PMID: 36396925 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases